Search
Risedronic acid
go.drugbank.com/drugs/DB00884ApprovedInvestigationalRisedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111].
Categories: Drugs for Treatment of Bone DiseasesAbacavir
go.drugbank.com/drugs/DB01048ApprovedInvestigationalAbacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclop...
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseVidarabine
go.drugbank.com/drugs/DB00194ApprovedWithdrawnA nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a...
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseRaxibacumab
go.drugbank.com/drugs/DB08902ApprovedInvestigationalRaxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA tech...
Categories: Antiinfectives for Systemic Usealpha-Tocopherol succinate
go.drugbank.com/drugs/DB14001ApprovedNutraceuticalVet approvedAt the moment, however, there exists a lack of formal data and evidence to support any such additional indications for vitamin E use. … Alpha-tocopherol succinate is subsequently most commonly indicated for dietary supplementation in individuals who may demonstrate a genuine deficiency in vitamin E.
Mixtures: For MenDefactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53198,L53208] FAK is important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key … [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian
Clonazepam
go.drugbank.com/drugs/DB01068ApprovedIllicitInvestigational[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder. … Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year.
Mipomersen
go.drugbank.com/drugs/DB05528ApprovedMipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels o...
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaPrasterone
go.drugbank.com/drugs/DB01708ApprovedInvestigationalNutraceuticalIn the United States, DHEA or DHEAS have been advertised with claims that they may be beneficial for a wide variety of ailments.
Categories: Anabolic Agents for Systemic UseVericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigational[L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure. … to its structure have dramatically decreased its susceptibility to oxidative metabolism,[A227458] resulting in a relatively long half-life and allowing for once-daily dosing.